KR102347243B1 - Composition for anti-virus comprising Quillaia saponaria - Google Patents
Composition for anti-virus comprising Quillaia saponaria Download PDFInfo
- Publication number
- KR102347243B1 KR102347243B1 KR1020210023660A KR20210023660A KR102347243B1 KR 102347243 B1 KR102347243 B1 KR 102347243B1 KR 1020210023660 A KR1020210023660 A KR 1020210023660A KR 20210023660 A KR20210023660 A KR 20210023660A KR 102347243 B1 KR102347243 B1 KR 102347243B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- coronavirus
- quillaja
- cov
- sars
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 241000219287 Saponaria Species 0.000 title claims description 14
- 230000002155 anti-virotic effect Effects 0.000 title abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 87
- 235000009001 Quillaja saponaria Nutrition 0.000 claims abstract description 64
- 241000711573 Coronaviridae Species 0.000 claims abstract description 19
- 241001092473 Quillaja Species 0.000 claims description 57
- 239000004480 active ingredient Substances 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 19
- 239000002537 cosmetic Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 241001092142 Molina Species 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 11
- 241000315672 SARS coronavirus Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 241001678559 COVID-19 virus Species 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 abstract description 9
- 230000001877 deodorizing effect Effects 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 208000035473 Communicable disease Diseases 0.000 abstract description 5
- 241001454523 Quillaja saponaria Species 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 description 28
- -1 environment Substances 0.000 description 28
- 235000013305 food Nutrition 0.000 description 26
- 238000009472 formulation Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 239000006210 lotion Substances 0.000 description 10
- 229930182490 saponin Natural products 0.000 description 10
- 150000007949 saponins Chemical class 0.000 description 10
- 235000017709 saponins Nutrition 0.000 description 10
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 9
- 239000010282 Emodin Substances 0.000 description 9
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 9
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 9
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000000774 hypoallergenic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000004176 Alphacoronavirus Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000711467 Human coronavirus 229E Species 0.000 description 2
- 241000482741 Human coronavirus NL63 Species 0.000 description 2
- 241001428935 Human coronavirus OC43 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 241000694414 Sapindus saponaria Species 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- MQUFAARYGOUYEV-UHFFFAOYSA-N 9-formyl-5,10-dihydroxy-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1CC(O)C(C)(C=O)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MQUFAARYGOUYEV-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- MQUFAARYGOUYEV-UWEXFCAOSA-N Quillaic acid Natural products CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@H]4[C@@]5(C)CC[C@H](O)[C@](C)(C=O)[C@H]5CC[C@@]34C)[C@H]2C1)C(=O)O MQUFAARYGOUYEV-UWEXFCAOSA-N 0.000 description 1
- 241000696038 Quillajaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000005002 finish coating Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- MQUFAARYGOUYEV-UAWZMHPWSA-N quillaic acid Chemical compound C1C[C@H](O)[C@@](C)(C=O)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@@H](O)[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MQUFAARYGOUYEV-UAWZMHPWSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
바이러스 부착 방지제 또는 항바이러스용 조성물에 관한 것이다.It relates to a composition for preventing virus adhesion or antiviral.
비누나무라고 불리는 퀼라야(Quillaia saponaria M.)는 남미의 칠레, 볼리비아, 페루 지역에 분포하는 장미과 상록교목이다. 남미 원주민이 나무의 껍질을 벗겨내 물에 담근 후, 비누처럼 세탁이나 머리 세정으로 사용하였다. 여러 나라에서 음료, 특히 무알코올 음료나 쉐이크 드링크의 기포제 등으로 사용되어 왔다. 퀼라야 추출물은 식품 용도 이외에도, 식품, 화장품, 의약품, 세제, 건축재료, 폐수처리 등 다양한 방면으로 폭넓게 사용되고 있다. 지금까지 알려진 퀼라야의 생리활성 효능은 대부분 유효 성분인 트리터페노이드계 사포닌(triterpenoid saponins)에 기인한 것이며, 이중 퀼라야 사포제닌(Quillaja sapogenin)과 킬라익산(Quillaic acid)이 주요 성분이다. 이러한 사포닌 성분들은 계면 활성 작용, 용혈 작용, 항균 작용, 동물 성장 촉진 작용, 콜레스테롤과 복합체 형성 작용 등의 여러 유익한 기능을 가지고 있는 것으로 알려져 있다. 이러한 기능으로 인해 사료, 의약, 환경, 화장품과 같은 다양한 산업 분야에서 기능성 첨가제로 이용되고 있다(Waller, G., Yamasaki, K., Saponins used in traditional and Modern medicine, 1996). Quillaia (Quillaia saponaria M. ), also called soap tree, is a rosaceae evergreen tree distributed in Chile, Bolivia, and Peru in South America. Native Americans peeled the bark of the tree, soaked it in water, and used it as soap for washing or washing hair. It has been used as a foaming agent in beverages, particularly non-alcoholic beverages and shake drinks, in many countries. In addition to food uses, Quillaja extract is widely used in various fields such as food, cosmetics, pharmaceuticals, detergents, building materials, and wastewater treatment. Most of the bioactive efficacy of Quillaja known so far is due to the active ingredient, triterpenoid saponins, of which Quillaja sapogenin and Quillaic acid are the main ingredients. These saponin components are known to have several beneficial functions, such as surfactant action, hemolysis action, antibacterial action, animal growth promotion action, and cholesterol-complex formation action. Due to these functions, it is used as a functional additive in various industrial fields such as feed, medicine, environment, and cosmetics (Waller, G., Yamasaki, K., Saponins used in traditional and Modern medicine, 1996).
코로나바이러스(CoV)는 사람과 다양한 동물에 감염될 수 있는 바이러스로서 유전자 크기가 27~32kb의 RNA 바이러스이다. 코로나바이러스과에는 4개의 속(알파, 베타, 감마, 델타)으로 분류 할 수 있다. 알파와 베타는 사람과 동물에게 감염될 수 있으며, 감마와 델타는 동물에게만 감염된다. 형태는 코로나 바이러스의 명명과 같이 전자현미경 관찰시 구형을 나타내며, 외부 spike 단백질이 크라운 형태로 특징을 나타낸다. 사람감염 코로나바이러스는 현재까지 6종류가 알려져 있다. 감기를 일으키는 유형으로는 229E, OC43, NL63, HKU1이 있으며, 중증 폐렴을 일으킬 수 있는 유형인 SARS-CoV와 MERS-CoV가 있다. 그리고 2019년부터 발생한 신규 코로나바이러스는 SARS-CoV-2로 감염시 발열, 권태감, 기침, 호흡곤란, 및 폐렴 등 경증에서 중증까지 다양한 호흡기감염증이 나타난다. 그 외 가래, 인후통, 두통, 객혈과 오심, 설사 등도 나타난다. 우리나라의 제1급 감염병 신종 감영병 증후군으로 법정감염병으로 분류되며, 비말, 접촉을 통해 전파된다. 잠복기는 1일에서 14일이며, 전세계 치명률은 약 3.4%(WHO, 3.5 기준)로 아직까지 치료제가 없는 실정이다(질병관리본부, http://ncov.mohw.go.kr/).Coronavirus (CoV) is a virus that can infect humans and various animals, and is an RNA virus with a gene size of 27 to 32 kb. Coronaviridae can be classified into four genera (alpha, beta, gamma, delta). Alpha and beta can infect humans and animals, while gamma and delta only infect animals. The shape shows a spherical shape when observed under an electron microscope, as in the name of the corona virus, and the external spike protein is characterized as a crown shape. There are six types of human-infecting coronaviruses known so far. Types that cause cold include 229E, OC43, NL63, and HKU1, and SARS-CoV and MERS-CoV can cause severe pneumonia. In addition, the new coronavirus that has occurred since 2019 is SARS-CoV-2, which causes various respiratory infections, ranging from mild to severe, such as fever, malaise, cough, shortness of breath, and pneumonia. In addition, sputum, sore throat, headache, hemoptysis, nausea, and diarrhea may also occur. Korea's first-class infectious disease, novel infectious disease syndrome, classified as a legal infectious disease and spread through droplets and contact. The incubation period is 1 to 14 days, and the worldwide fatality rate is about 3.4% (WHO, 3.5 standards), and there is no treatment yet (Centers for Disease Control, http://ncov.mohw.go.kr/).
퀼라야추출물은 Reovirus(위장염), Vaccinia Virus(두창), VZV(대상포진), HSV-1(허피스), HIV-1 과 HIV-2(자가면역질환), Rotavirus(설사유발)에 대한 바이러스 감염에 저항하는 것으로 알려져 있다(Michael R Roner et al, Antiviral acivity ovtained from aqueous extracts of the Chilean soapbark tree, 2007, Michael R Roner et al, Prevention of rotavirus infections in vitro with aqueous extracts of Quillaja saponaria Molina). 하지만 코로나바이러스 종류에 대한 감염 저항에 대해 보고된 바가 없다.Quillaja extract is a viral infection against Reovirus (gastroenteritis), Vaccinia Virus (pox), VZV (herpes zoster), HSV-1 (herpes), HIV-1 and HIV-2 (autoimmune disease), Rotavirus (causing diarrhea) (Michael R Roner et al, Antiviral activity ovtained from aqueous extracts of the Chilean soapbark tree, 2007, Michael R Roner et al, Prevention of rotavirus infections in vitro with aqueous extracts of Quillaja saponaria Molina). However, there have been no reports of infection resistance to this type of coronavirus.
삭제delete
일 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 항바이러스성 약학적 조성물을 제공하는 것이다.One aspect is to provide an antiviral pharmaceutical composition containing the Quillaya (Quillaia saponaria Molina) extract as an active ingredient.
다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 항바이러스용 피부외용제를 제공하는 것이다.Another aspect is to provide an antiviral external skin preparation containing an extract of Quillaia saponaria Molina as an active ingredient.
또 다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 항바이러스용 건강기능식품 조성물을 제공하는 것이다.Another aspect is to provide an antiviral health functional food composition containing an extract of Quillaia (Quillaia saponaria Molina) as an active ingredient.
또 다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 바이러스 부착 방지 의약외품 조성물을 제공하는 것이다.Another aspect is to provide an anti-viral quasi-drug composition containing an extract of Quillaia saponaria Molina as an active ingredient.
또 다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 항바이러스성 화장료 조성물을 제공하는 것이다.Another aspect is to provide an antiviral cosmetic composition containing the Quillaia (Quillaia saponaria Molina) extract as an active ingredient.
또 다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 소취용 조성물을 제공하는 것이다.Another aspect is to provide a deodorizing composition containing the Quillaya (Quillaia saponaria Molina) extract as an active ingredient.
또 다른 양상은 퀼라야(Quillaia saponaria Molina) 추출물을 유효성분으로 함유하는 소취용 화장료 조성물을 제공하는 것이다.Another aspect is to provide a cosmetic composition for deodorization containing Quillaya (Quillaia saponaria Molina) extract as an active ingredient.
일 양상은 퀼라야 추출물을 유효성분으로 함유하는 항바이러스성 약학적 조성물을 제공하는 것이다.One aspect is to provide an antiviral pharmaceutical composition containing the Quillaja extract as an active ingredient.
본 명세서에서"퀼라야"란, 남미의 칠레, 볼리비아, 페루 지역에 분포하는 키라야과(Quillajaceae) 상록교목을 의미할 수 있다. 학명은 Quillaia saponaria MOLINA로 칠레가 원산지이며, 주로 해발 2000m에서 서식한다. 15-20m정도 자라고 두껍고 어두운 나무 껍질과 3-5㎝ 길이의 매끄럽고 타원형의 잎을 가진다. 비누나무라고도 부르며 안쪽 나무껍질에는 일종의 천연 비누인 사포닌을 함유하고 있다.As used herein, "quillaya" may mean an evergreen tree of the family Quillajaceae distributed in Chile, Bolivia, and Peru in South America. Its scientific name is Quillaia saponaria MOLINA , and it is native to Chile and inhabits mainly at an altitude of 2000 m above sea level. It grows to about 15-20 m and has thick, dark bark and smooth, oval leaves of 3-5 cm in length. Also called soap tree, the inner bark contains saponin, a kind of natural soap.
본 명세서에서 "추출물"은 목적하는 물질을 다양한 용매에 침지한 다음, 상온 또는 가온상태에서 일정시간 동안 추출하여 수득한 액상성분 또는 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미할 수 있다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물 및 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다.As used herein, the term "extract" refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it for a certain period of time at room temperature or in a heated state, or a product such as a solid obtained by removing the solvent from the liquid component. can In addition, in addition to the result, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their preparations and purified products, and the like.
상기 추출물은 퀼라야 추출물일 수 있다. 추출용매로는 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜, 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미세결정 셀룰로오스, 알루미늄 메타하이드록사이드, 벤토나이트, 아가 또는 트라가칸트, 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세라이드, 지방산 디에탄올아미드, 식물성 오일, 리놀린 유도체, 또는 에톡실화 글리세롤 지방산 에스테르 등을 포함할 수 있다. 구체적으로, 상기 추출용매는 극성용매, 비극성용매 또는 이들의 조합일 수 있다. 상기 극성용매로는 물, 탄소수 1 내지 6의 무수 또는 함수 알코올(메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올 또는 2-부톡시에탄올 등) 또는 알코올성 화합물(에틸렌글리콜, 프로필렌글리콜 또는 부틸렌글리콜 등), 아세트산, DMFO(dimethyl-formamide), DMSO(dimethyl sulfoxide) 또는 이들의 조합일 수 있고, 비극성 용매로는 헥산, 오로알칸, 펜탄, 헥산, 에틸아세테이트, 메틸아세테이트, 부틸아세테이트, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 아세톤, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 디에틸에테르, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소, THF 또는 이들의 조합일 수 있다. 본 명세서에서 상기 추출물은 특별히 이에 제한되지 않으며, 상기 용매뿐만 아니라 다른 용매를 이용하여 제조한 실질적으로 동일한 효과를 나타내는 추출물을 포함하는 것일 수 있다.The extract may be a Quillaja extract. Extraction solvents include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, liquid diluent, ethoxylated isostearyl alcohol , suspending agents such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, Isethionate, imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative, or ethoxy sylated glycerol fatty acid esters; and the like. Specifically, the extraction solvent may be a polar solvent, a non-polar solvent, or a combination thereof. As the polar solvent, water, anhydrous or hydrous alcohols having 1 to 6 carbon atoms (methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol or 2-butoxyethanol, etc.) or It may be an alcoholic compound (ethylene glycol, propylene glycol or butylene glycol, etc.), acetic acid, dimethyl-formamide (DMFO), dimethyl sulfoxide (DMSO), or a combination thereof, and the non-polar solvent includes hexane, oroalkane, pentane, hexane, Ethyl acetate, methyl acetate, butyl acetate, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, acetone, 1-chloropentane, o-xyl Rene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, diethyl ether, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline , diethylamine, ether, carbon tetrachloride, THF, or a combination thereof. In the present specification, the extract is not particularly limited thereto, and may include an extract having substantially the same effect prepared using other solvents as well as the solvent.
일 구체예에 있어서, 상기 용매를 이용하여 추출하는 방법은 당업계에서 공지된 방법에 따라 수행할 수 있다. 예컨데, 퀼라야를 상기 용매에 침지하고, 10 내지 25℃의 상온에서 추출하는 냉침추출법, 40 내지 100℃로 가열하여 추출하는 가 열추출법, 환류냉각기를 이용한 환류추출법, 초음파기기를 이용한 초음파 추출법 및 고주파 기기를 이용한 고주파 추출법 등의 방법을 통하여 수행할 수 있다.In one embodiment, the extraction using the solvent may be performed according to a method known in the art. For example, cold extraction method in which Quillaja is immersed in the solvent and extracted at room temperature of 10 to 25 ° C., heating extraction method in which extraction is performed by heating to 40 to 100 ° C., reflux extraction method using a reflux condenser, ultrasonic extraction method using an ultrasonic device, and It can be performed through a method such as a high-frequency extraction method using a high-frequency device.
일 구체예에 있어서, 상기 바이러스는 코로나 바이러스일 수 있다. 상기 코로나 바이러스는 알파코로나바이러스, 베타코로나바이러스, 감마코로나바이러스, 델타코로나바이러스, 인간 코로나바이러스 229E(HCoV-229E), 인간 코로나바이러스 OC43(HCoV-OC43), 중증급성호흡기증후군 코로나바이러스(SARS-CoV), 인간 코로나바이러스 NL63 (HCoV-NL63, 뉴헤븐 코로나바이러스), 인간 코로나바이러스 HKU1, 중동호흡기증후군 코로나바이러스(MERS-CoV) 또는 중증급성호흡기증후군 코로나바이러스 2(SARS-Cov-2 또는 2019 novel coronavirus 또는 2019-nCoV)일 수 있다.In one embodiment, the virus may be a corona virus. The coronavirus is alpha coronavirus, beta coronavirus, gamma coronavirus, delta coronavirus, human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), severe acute respiratory syndrome coronavirus (SARS-CoV) ), human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), human coronavirus HKU1, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2 or 2019 novel coronavirus) or 2019-nCoV).
본 명세서에서 "항바이러스"란, 코로나바이러스 입자 생성을 억제하는 능력, 즉 숙주세포, 특히 인간을 포함하는 포유동물에서 코로나바이러스의 형성 및/또는 복제를 효과적으로 억제하는 능력을 의미할 수 있다. 상기 퀼라야 추출물을 유효 성분으로 하는 조성물들은 바이러스 감염, 복제 또는 증식 등에 필요한 기작을 방해하여 항바이러스적 효과를 가질 수 있다.As used herein, "antiviral" may refer to the ability to inhibit the production of coronavirus particles, that is, the ability to effectively inhibit the formation and/or replication of a coronavirus in a host cell, particularly a mammal, including a human. Compositions using the Quillaja extract as an active ingredient may have an antiviral effect by interfering with mechanisms necessary for viral infection, replication or proliferation, etc.
일 구체예에 따른 상기 또는 하기 조성물 내 퀼라야 추출물의 함량은 0.0001 내지 100 중량%, 0.001 내지 100 중량%, 0.01 내지 100 중량%, 0.1 내지 100 중량%, 1 내지 100 중량%, 10 내지 100 중량%, 0.0001 내지 80 중량%, 0.001 내지 80 중량%, 0.01 내지 80 중량%, 0.1 내지 80 중량%, 1 내지 80 중량%, 10 내지 80 중량%, 0.0001 내지 70 중량%, 0.001 내지 70 중량%, 0.01 내지 70 중량%, 0.1 내지 70 중량%, 1 내지 70 중량%, 10 내지 70 중량%, 0.0001 내지 60 중량%, 0.001 내지 60 중량%, 0.01 내지 60 중량%, 0.1 내지 60 중량%, 1 내지 60 중량%, 10 내지 60 중량%, 0.0001 내지 50 중량%, 0.001 내지 50 중량%, 0.01 내지 50 중량%, 0.1 내지 50 중량%, 1 내지 50 중량%, 10 내지 50 중량%, 0.0001 내지 40 중량%, 0.001 내지 40 중량%, 0.01 내지 40 중량%, 0.1 내지 40 중량%, 1 내지 40 중량%, 10 내지 40 중량%, 0.0001 내지 30 중량%, 0.001 내지 30 중량%, 0.01 내지 30 중량%, 0.1 내지 30 중량%, 1 내지 30 중량%, 10 내지 30 중량%, 0.0001 내지 20 중량%, 0.001 내지 20 중량%, 0.01 내지 20 중량%, 0.1 내지 20 중량%, 1 내지 20 중량%, 10 내지 20 중량%, 0.0001 내지 10 중량%, 0.001 내지 10 중량%, 0.1 내지 10 중량% 또는 1 내지 10 중량%일 수 있다.The content of the Quillaja extract in the above or below composition according to an embodiment is 0.0001 to 100% by weight, 0.001 to 100% by weight, 0.01 to 100% by weight, 0.1 to 100% by weight, 1 to 100% by weight, 10 to 100% by weight %, 0.0001 to 80% by weight, 0.001 to 80% by weight, 0.01 to 80% by weight, 0.1 to 80% by weight, 1 to 80% by weight, 10 to 80% by weight, 0.0001 to 70% by weight, 0.001 to 70% by weight, 0.01 to 70% by weight, 0.1 to 70% by weight, 1 to 70% by weight, 10 to 70% by weight, 0.0001 to 60% by weight, 0.001 to 60% by weight, 0.01 to 60% by weight, 0.1 to 60% by weight, 1 to 60 wt%, 10-60 wt%, 0.0001-50 wt%, 0.001-50 wt%, 0.01-50 wt%, 0.1-50 wt%, 1-50 wt%, 10-50 wt%, 0.0001-40 wt% %, 0.001 to 40% by weight, 0.01 to 40% by weight, 0.1 to 40% by weight, 1 to 40% by weight, 10 to 40% by weight, 0.0001 to 30% by weight, 0.001 to 30% by weight, 0.01 to 30% by weight, 0.1 to 30% by weight, 1 to 30% by weight, 10 to 30% by weight, 0.0001 to 20% by weight, 0.001 to 20% by weight, 0.01 to 20% by weight, 0.1 to 20% by weight, 1 to 20% by weight, 10 to 20% by weight, 0.0001 to 10% by weight, 0.001 to 10% by weight, 0.1 to 10% by weight or 1 to 10% by weight.
일 구체예에 따른 상기 조성물의 투여 횟수는 1일 1내지 3회 또는 필요에 따라 초과하여 투여할 수 있다. 다만, 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성별, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반 응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있고, 당업자라면 이러한 요인들을 고려하여 투여량을 적절히 조절할 수 있다. 투여 횟수는 1회 또는 임상적으로 용인가능한 부작용의 범위 내에서 2회 이상이 가능하고, 투여 부위에 대해서도 1개소 또는 2개소 이상에 투여할 수 있다. 인간 이외의 동물에 대해서도, ㎏당 인간과 동일한 투여량으로 하거나, 또는 예를 들면 목적의 동물과 인간과의 기관(심장 등)의 용적비(예를 들면, 평균값) 등으로 상기의 투여량을 환산한 양을 투여할 수 있다. 가능한 투여 경로에는 경구, 설하, 비경구 (예를 들어, 피하, 근육내, 동맥내, 복강내, 경막내, 또는 정맥내), 직장, 국소 (경피 포함), 흡입, 및 주사, 또는 이 식성 장치 또는 물질의 삽입을 포함할 수 있다. 일 구체예에 따른 치료의 대상동물로서는, 인간 및 그 밖의 목적으로 하는 포유동물을 예로 들 수 있고, 구체적으로는 인간, 원숭이, 마우스, 랫트, 토끼, 양, 소, 개, 말, 돼지 등이 포함된다. 다만, 상기 투여량, 횟수 및 대상은 본 명세서에서 범위를 한정하는 것은 아니다.The number of times of administration of the composition according to one embodiment may be administered in excess of 1 to 3 times a day or as needed. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity, those skilled in the art If so, the dosage can be appropriately adjusted in consideration of these factors. The number of administration may be one time or two or more within the range of clinically acceptable side effects, and may be administered to one or two or more sites for the administration site. For animals other than humans, the same dose as that of humans per kg or, for example, the above dose is converted by the volume ratio (for example, average value) of the target animal and the organ (heart, etc.) of the human One dose can be administered. Possible routes of administration include oral, sublingual, parenteral (eg, subcutaneous, intramuscular, intraarterial, intraperitoneal, intrathecal, or intravenous), rectal, topical (including transdermal), inhalation, and injection, or implantation. It may involve the insertion of a device or material. Examples of the animal to be treated according to one embodiment include humans and other target mammals, specifically humans, monkeys, mice, rats, rabbits, sheep, cattle, dogs, horses, pigs, etc. Included. However, the dosage, number, and subject are not limited in the scope of the present specification.
일 구체예에 따른 상기 약학적 조성물은 약학적으로 허용가능한 담체 및/또는 첨가물을 포함할 수 있다. 예를 들어, 멸균수, 생리식염수, 관용의 완충제(인산, 구연산, 그 밖의 유기산 등), 안정제, 염, 산화방지제(아스코르브산 등), 계면활성제, 현탁제, 등장화제, 또는 보존제 등을 포함할 수 있다. 국소 투여를 위해, 생체고분자(biopolymer) 등의 유기물, 하이드록시아파타이트 등의 무기물, 구체적으로는 콜라겐 매트릭스, 폴리락트산 중합체 또는 공중합체, 폴리에틸렌글리콜 중합체 또는 공중합체 및 그의 화학적 유도체 등과 조합시키는 것도 포함할 수 있다.The pharmaceutical composition according to one embodiment may include a pharmaceutically acceptable carrier and/or additive. For example, sterile water, physiological saline, conventional buffers (phosphoric acid, citric acid, other organic acids, etc.), stabilizers, salts, antioxidants (ascorbic acid, etc.), surfactants, suspending agents, isotonic acid, or preservatives, etc. can do. For topical administration, organic materials such as biopolymers, inorganic materials such as hydroxyapatite, specifically collagen matrix, polylactic acid polymers or copolymers, polyethylene glycol polymers or copolymers and chemical derivatives thereof, etc. may also be combined for topical administration. can
일 구체예에 따른 상기 약학적 조성물은 그 투여방법이나 제형에 따라 필요한 경우, 현탁제, 용해보조제, 안정화제, 등장화제, 보존제, 흡착방지제, 계면활성화제, 희석제, 부형제, pH 조정제, 무통화제, 완충제, 환원제, 산화방 지제 등을 적절히 포함할 수 있다. 일 구체예에 따른 약학적 조성물은 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질 중의 용액, 현탁액 또는 유화액 형태이거나 분말, 과립, 정제 또는 캡슐 형태일 수 있다.The pharmaceutical composition according to one embodiment is a suspending agent, solubilizing agent, stabilizer, isotonic agent, preservative, anti-adsorption agent, surfactant, diluent, excipient, pH adjuster, analgesic agent, if necessary according to the administration method or dosage form , a buffer, a reducing agent, an antioxidant, and the like may be included as appropriate. The pharmaceutical composition according to one embodiment is formulated in a unit dosage form by using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. It may be prepared as or by putting it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of a powder, granules, tablets or capsules.
다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 항바이러스용 피부외용제를 제공하는 것이다.Another aspect is to provide an antiviral external skin preparation containing Quillaja extract as an active ingredient.
이때, 상기 퀼라야, 추출물, 바이러스 및 항바이러스의 의미는 상기에서 설명한 바와 같다.At this time, the meaning of the Quillaja, the extract, the virus and the antiviral is the same as described above.
본 명세서에서 "외용제"는 외용으로 제공되는 제제일 수 있고, 피부 외용제 조성물은 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유하여 제형화된 것일 수 있다. 이는 국소적용에 적합한 모든 제형으로서, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이, 팩 또는 콘실 스틱의 형태로 제공될 수 있다. 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있으나, 이에 제한되는 것은 아니다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.As used herein, "external preparation" may be a preparation provided for external use, and the composition for external application for skin may be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example, solutions, gels, solids, kneaded dry products, emulsions obtained by dispersing the oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or, ionic (liposomes) and It may be provided in the form of a non-ionic vesicular dispersant, or in the form of a cream, skin, lotion, powder, ointment, spray, pack or concealer stick. It may be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant, but is not limited thereto. These compositions can be prepared according to conventional methods in the art.
상기 피부외용제 조성물은 항바이러스 효과를 가질 수 있다.The composition for external application for skin may have an antiviral effect.
또 다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 항바이러스용 건강기능식품 조성물을 제공하는 것이다.Another aspect is to provide an antiviral health functional food composition containing the Quillaja extract as an active ingredient.
이때, 상기 퀼라야, 추출물, 바이러스 및 항바이러스의 의미는 상기에서 설명한 바와 같다.At this time, the meaning of the Quillaja, the extract, the virus and the antiviral is the same as described above.
본 명세서에서 "식품"이란, 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료, 비타민 복합제, 건강기능식품 및 건강식품 등일 수 있으며, 통상적인 의미에서의 식품을 모두 포함할 수 있다As used herein, "food" means meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, It may be a vitamin complex, health functional food, health food, etc., and may include all foods in a conventional sense.
일 구체예에 따른 상기 식품 조성물은 일상적으로 섭취하는 것이 가능하고, 우수한 항바이러스 효과를 기대할 수 있으므로, 건강 증진 목적으로 매우 유용하게 사용될 수 있다.The food composition according to one embodiment can be ingested on a daily basis and can be expected to have an excellent antiviral effect, so it can be very usefully used for health promotion purposes.
본 명세서에서 "건강 기능(성) 식품(functional food)"이란, 특정보건용 식품(food for special health use, FoSHU)과 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미할 수 있다. 여기서 '기능(성)'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미할 수 있다. 본 명세서에서 식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 식품의 제형 또한 식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 명세서에서 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나므로, 일 구체예에 따른 상기 식품은 항바이러스 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present specification, "functional food (functional food)" is the same term as food for special health use (FoSHU). It may mean a food with a high medical effect. Here, the term 'function (sex)' may refer to obtaining useful effects for health purposes, such as regulating nutrients or physiological effects with respect to the structure and function of the human body. In the present specification, food can be prepared by a method commonly used in the art, and during the preparation, raw materials and components commonly added in the art can be added to prepare the food. In addition, the formulation of the food may be prepared without limitation as long as it is a formulation recognized as a food. In the present specification, the composition for food can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long period of time using food as a raw material, and because it is excellent in portability, The food according to the embodiment can be ingested as an adjuvant for enhancing the antiviral effect.
상기 건강 식품(health food)은 일반식품에 비해 적극적인 건강유지나 증진 효과를 가지는 식품을 의미할 수 있고, 건강보조식품(health supplement food)은 건강보조 목적의 식품을 의미할 수 있다. 경우에 따라, 건강 기능 식품, 건강식품 또는 건강보조식품의 용어는 혼용될 수 있다.The health food may mean a food having an active health maintenance or promotion effect compared to general food, and the health supplement food may mean a food for the purpose of health supplementation. In some cases, the terms health functional food, health food, or health supplement may be used interchangeably.
상기 건강 기능 식품은 상기 조성물을 음료, 차류, 향신료, 껌 또는 과자류 등의 식품 소재에 첨가하거나, 캡슐화, 분말화 또는 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미할 수 있으나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용이 없는 장점이 있을 수 있다.The health functional food is a food prepared by adding the composition to food materials such as beverages, teas, spices, gum or confectionery, or encapsulating, powdering, or suspension, etc. It may mean, but unlike general drugs, there may be an advantage in that there are no side effects that may occur when taking a drug for a long time using food as a raw material.
상기 건강 기능 식품 조성물은 생리학적으로 허용 가능한 담체를 추가로 포함할 수 있는데, 담체의 종류는 특별히 제한되지 않으며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다.The health functional food composition may further include a physiologically acceptable carrier, the type of carrier is not particularly limited and any carrier commonly used in the art may be used.
또한, 상기 건강 기능 식품 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate) 및 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 및 크륨(Cr) 등의 미네랄; 및 라이신, 트립토판, 시스테인 및 발린 등의 아미노산을 포함할 수 있다.In addition, the health functional food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate and pantothenic acid may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); and amino acids such as lysine, tryptophan, cysteine and valine.
또한, 상기 식품 조성물은 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산 및 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분 및 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA) 및 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨 및 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 및 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린 및 나트륨 등), 향료(바닐린 및 락톤류 등), 팽창제(명반 및 D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제 또는 개량제 등의 식품첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.In addition, the food composition includes preservatives (potassium sorbate, sodium benzoate, salicylic acid and sodium dehydroacetate, etc.), disinfectants (bleaching powder and high bleaching powder and sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA) and butylhydro oxytoluene (BHT), etc.), coloring agents (tar pigments, etc.), coloring agents (sodium nitrite and sodium nitrite, etc.), bleach (sodium sulfite), seasonings (MSG and sodium glutamate, etc.), sweeteners (dulcin, cyclmate, saccharin and sodium), fragrances (vanillin and lactones, etc.), swelling agents (alum and potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (foams), film agents, gum base agents, foam inhibitors, solvents or improving agents, etc. It may contain food additives. The additive may be selected according to the type of food and used in an appropriate amount.
일 구체예에 따른 상기 식품 조성물은 건강음료 조성물일 수 있다. 상기 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강음료 조성물 100㎖ 당 0.01 내지 0.04g, 구체적으로 약 0.02 내지 0.03g이 될 수 있으며 이에 한정되지 않은다.The food composition according to one embodiment may be a health drink composition. The health beverage composition may contain various flavoring agents or natural carbohydrates as additional ingredients, like a conventional beverage. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as taumatine, stevia extract; A synthetic sweetener such as saccharin or aspartame may be used. The ratio of the natural carbohydrate may be 0.01 to 0.04 g, specifically, about 0.02 to 0.03 g per 100 ml of the health beverage composition of the present invention, but is not limited thereto.
상기 외에 건강음료 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유 할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강음료 조성물 100 중량부당 0.01 내지 1.0 중량부의 범위에서 선택될 수 있다.In addition to the above, the health drink composition includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid, pectic acid salts, alginic acid, alginic acid salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain alcohol, a carbonation agent, or the like. In addition, it may contain the pulp for the production of natural fruit juice, fruit juice beverage, or vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not very important, but may be selected from 0.01 to 1.0 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
또 다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 바이러스 부착 방지 의약외품 조성물을 제공하는 것이다.Another aspect is to provide an anti-virus quasi-drug composition containing the Quillaja extract as an active ingredient.
이때, 상기 퀼라야, 추출물 및 바이러스의 의미는 상기에서 설명한 바와 같다.At this time, the meaning of the Quillaja, the extract and the virus is the same as described above.
본 명세서에서 "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미할 수 있다. 예를 들어 대한민국 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람ㆍ동물의 질병 치료나 예방에 쓰이는 제품 및 인체에 대한 작용이 경미하거나 직접 작용하지 않는 제품 등이 포함될 수 있다.As used herein, "quasi-drugs" may refer to articles with a milder action than pharmaceuticals among articles used for the purpose of diagnosing, treating, improving, alleviating, treating, or preventing diseases of humans or animals. For example, according to the Pharmaceutical Affairs Act of the Republic of Korea, quasi-drugs exclude products used for medicinal purposes, and may include products used for the treatment or prevention of diseases in humans and animals, and products with minor or no direct action on the human body.
상기 의약외품 조성물은 바디 클렌저, 폼, 비누, 마스크, 연고제, 크림, 로션, 에센스 및 스프레이로 이루어진 군에서 선택되는 형태로 제조할 수 있으나, 이에 제한되는 것은 아니다.The quasi-drug composition may be prepared in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence and spray, but is not limited thereto.
상기 의약외품 조성물은 상기 퀼라야 추출물을 유효성분으로 포함하는 조성물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다.The quasi-drug composition may be used as it is by adding the composition comprising the Quillaja extract as an active ingredient or in combination with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method.
또 다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 항바이러스성 화장료 조성물을 제공하는 것이다.Another aspect is to provide an antiviral cosmetic composition containing the Quillaja extract as an active ingredient.
이때, 상기 퀼라야, 추출물, 바이러스 및 항바이러스의 정의는 상기에서 설명한 바와 같다.At this time, the definitions of the Quillaja, the extract, the virus and the antiviral are as described above.
상기 화장료 조성물은 용액, 외용 연고, 크림, 폼, 영양 화장수, 유연 화장수, 스킨소프너, 스킨토너, 아스트린젠트, 향수, 팩, 유연수, 유액, 메이크업 베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린 크림, 선 오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 밀크로션, 모이스쳐 로션, 영양 로션, 마사지크림, 영양 크림, 모이스쳐 크림, 핸드크림, 파운데이션, 에센스, 영양 에센스, 팩, 파우더, 비누, 계면 활성제-함유 클렌징, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패치, 마스크팩, 에어로졸, 스프레이 및 캡슐로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다The cosmetic composition is a solution, external ointment, cream, foam, nourishing lotion, soft lotion, skin softener, skin toner, astringent, perfume, pack, soft water, emulsion, makeup base, essence, soap, liquid detergent, bath agent, sunscreen Cream, sun oil, suspension, emulsion, paste, gel, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, powder, soap, Formulation selected from the group consisting of surfactant-containing cleansing, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, oil, powder foundation, emulsion foundation, wax foundation, patch, mask pack, aerosol, spray and capsule can be manufactured, but is not limited thereto
상기 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다. 상기 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양할 수 있다.The cosmetic composition may further include one or more cosmetically acceptable carriers to be formulated in general skin cosmetics, and conventional ingredients include, for example, oil, water, surfactant, humectant, lower alcohol, thickener, chelating agent. , dyes, preservatives, fragrances, etc. may be appropriately mixed, but the present invention is not limited thereto. The cosmetically acceptable carrier included in the cosmetic composition may vary depending on the formulation.
상기 화장료 조성물의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the cosmetic composition is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide as a carrier component or mixtures thereof may be used.
상기 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and in particular, in the case of a spray, additionally propellants such as chlorofluorohydrocarbons, propane/butane or dimethyl ether.
상기 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용될 수 있다. 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier may be used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil , castor oil and sesame oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan can be used.
상기 화장료 조성물의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
상기 화장료 조성물의 제형이 캡슐인 경우에는, 알지네이트(alginate) 캡슐, 아가(agar) 캡슐, 젤라틴(gelatin) 캡슐, 왁스(wax)류 캡슐, 또는 이중 캡슐의 형태로 제형화될 수 있으며, 특별히 이에 제한되지 않는다.When the formulation of the cosmetic composition is a capsule, it may be formulated in the form of an alginate capsule, an agar capsule, a gelatin capsule, a wax capsule, or a double capsule, in particular not limited
또한, 상기 화장료 조성물은 퀼라야 추출물 이외에 통상적으로 이용되는 보조제, 예컨대 친수성 또는 친지성 겔화제, 친수성 또는 친지성 활성제, 보존제, 항산화제, 용매, 방향제, 충전제, 차단제, 안료, 흡취제 및 염료 등을 포함할 수 있다.In addition, the cosmetic composition may contain, in addition to the Quillaja extract, commonly used auxiliary agents, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, odorants and dyes, etc. may include
또 다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 소취용 조성물을 제공하는 것이다.Another aspect is to provide a deodorizing composition containing the Quillaja extract as an active ingredient.
이때, 상기 퀼라야 및 추출물의 의미, 상기 조성물 내 퀼라야 추출물 용량 및 조성물의 제형은 상기에서 설명한 바와 같다.At this time, the meaning of the Quillaja and the extract, the dosage of the Quillaja extract in the composition, and the formulation of the composition are as described above.
또 다른 양상은 퀼라야 추출물을 유효성분으로 함유하는 소취용 화장료 조성물을 제공한다.Another aspect provides a deodorizing cosmetic composition containing the Quillaja extract as an active ingredient.
이때, 상기 퀼라야, 추출물 및 화장료의 의미, 상기 조성물 내 퀼라야 추출물 용량 및 조성물의 제형은 상기에서 설명한 바와 같다.In this case, the meaning of the Quillaja extract and cosmetics, the amount of the Quillaja extract in the composition, and the formulation of the composition are as described above.
일 양상에 따른 퀼라야 추출물을 유효성분으로 함유하는 조성물은 코로나바이러스 에 대한 우수한 항바이러스 효과를 통해 바이러스 감염성 질환을 예방 또는 치료할 뿐만 아니라, 천연식물인 퀼라야 추출물을 이용하는 것이므로 재활용성 및 안전성이 인정되며, 소취 효과가 있어 일상생활 및 다양한 산업 분야에서 유용하게 사용될 수 있는 효과가 있다.The composition containing the Quillaja extract according to an aspect as an active ingredient not only prevents or treats viral infectious diseases through excellent antiviral effect on coronavirus, but also uses the Quillaja extract, a natural plant, so recyclability and safety are recognized It has a deodorizing effect, so it can be usefully used in daily life and various industrial fields.
도 1은 퀼라야 일반 추출물과 퀼라야 고주파 추출물과의 총사포닌 함량 차이를 나타낸 그래프이다. (실시예 1: 퀼라야 일반 추출물; 실시예 2: 퀼라야 고주파 추출물)
도 2는 Emodin의 항바이러스 효과를 나타낸 그래프이다.
도 3는 Emodin과 동일한 양의 퀼라야 고주파 추출물의 항바이러스 효과를 나타낸 그래프이다.1 is a graph showing the difference in total saponin content between Quillaya general extract and Quillaya high frequency extract. (Example 1: Quillaja general extract; Example 2: Quillaja radio frequency extract)
2 is a graph showing the antiviral effect of Emodin.
3 is a graph showing the antiviral effect of Quillaja high frequency extract in the same amount as Emodin.
이하, 본 명세서에서 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 명세서에서 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments are presented to aid understanding in the present specification. However, the following examples are only provided for easier understanding of the present invention, and the content is not limited in the present specification by the following examples.
실시예 1: 퀼라야 일반 추출물의 제조Example 1: Preparation of Quillaja common extract
건조 및 세절된 퀼라야 원료에 10~20배의 정제수를 가하여 80 ~ 90 ℃에서 2 ~ 3 시간 추출하고 상온까지 자연 냉각시킨다. 원심분리기를 이용하여 침전물을 제거하고 상등액을 채취하거나 여과지(Filter paper ADVANTEC, No.2, 110㎜)로 여과된 상등액을 추출물로 사용하였다.Add 10 to 20 times purified water to the dried and minced Quillaja raw materials, extract it at 80 ~ 90 ℃ for 2-3 hours, and naturally cool it to room temperature. The precipitate was removed using a centrifuge, and the supernatant was collected or the supernatant filtered with filter paper (Filter paper ADVANTEC, No. 2, 110 mm) was used as an extract.
실시예 2: 퀼라야 고주파 추출물의 제조Example 2: Preparation of Quillaja radio frequency extract
건조 및 세절된 퀼라야 원료에 10~20배의 정제수를 가한 후, 고주파기기(HS9760, ㈜올텍)를 이용하여 25℃ ~ 35℃ 온도에서 0.2 ~ 2㎒, 1분 ~ 10분 동안 80 ~ 90 kJ/㎏의 조건에서 추출하여 제조하였다. 원심분리기를 이용하여 침전물을 제거하고 상등액을 추출물로 사용하였다. After adding 10 to 20 times purified water to the dried and minced Quillaya raw materials, using a high-frequency device (HS9760, Alltech Co., Ltd.) at a temperature of 0.2 to 2 MHz at 25° C. to 35° C., 80 to 90 for 1 minute to 10 minutes It was prepared by extraction under the conditions of kJ/kg. The precipitate was removed using a centrifuge and the supernatant was used as an extract.
실험예 1: 퀼라야 일반 추출물과 퀼라야 고주파 추출물의 총 사포닌 함량 비교Experimental Example 1: Comparison of total saponin content of Quillaya general extract and Quillaya high frequency extract
상기 실시예 1의 퀼라야 일반 추출물과 상기 실시예 2의 퀼라야 고주파 추출물의 총 사포닌 함량을 비교 분석하기 위해 ㈜네이처앤바이오텍에 분석을 의뢰하였다.In order to compare and analyze the total saponin content of the Quillaya general extract of Example 1 and the Quillaya high frequency extract of Example 2, an analysis was requested from Nature & Biotech Co., Ltd.
상기 실시예 1에 따른 퀼라야 일반 추출물의 시험성적서 발급번호는 NNB-2020-N0978이며, 발행일은 2020년 9월 11일이다. 또한, 상기 실시예 2에 따른 퀼라야 고주파 추출물의 시험성적서 발급번호는 NNB-2020-N-0976이며, 발행일은 2020년 9월 11일이다.The test report issuance number of the general Quillaja extract according to Example 1 is NNB-2020-N0978, and the issuance date is September 11, 2020. In addition, the test report issuance number of the Quillaja high frequency extract according to Example 2 is NNB-2020-N-0976, and the issuance date is September 11, 2020.
도 1은 추출방식에 따른 퀼라야 추출물내의 총사포닌 함량을 나타낸다. 일반 추출물의 총 사포닌 함량은 2.67%인 반면, 고주파 추출물의 총 사포닌의 함량은 3.59%로, 추출물 내 총 사포닌 함량이 무려 36.46%나 증가하였다. 이러한 결과를 통해 고주파 추출방식의 효율성이 일반적인 추출방식의 효율성보다 더욱 우수함을 확인하였다. 1 shows the total saponin content in the Quillaja extract according to the extraction method. The total saponin content of the general extract was 2.67%, while the total saponin content of the high frequency extract was 3.59%, and the total saponin content in the extract increased by a whopping 36.46%. Through these results, it was confirmed that the efficiency of the high frequency extraction method is superior to that of the general extraction method.
실험예 2: 퀼라야 고주파 추출물의 피부 안전성 효과Experimental Example 2: Skin safety effect of Quillaja radio frequency extract
상기 실시예 2의 퀼라야 고주파 추출물의 피부 안전성에 대해 확인하기 위해 피부 첩포를 통한 일차 피부자극 시험을 실시하였다.In order to confirm the skin safety of the Quillaja radio frequency extract of Example 2, a primary skin irritation test was performed through a skin patch.
구체적으로, 등 부위에 정제수, 퀼라야 일반 추출물 또는 퀼라야 고주파 추출물을 각각 약 0.5g 포함하는 패치들을 부착하여 24시간 후에 제거 후, 30분 및 24시간, 48시간 후의 피부 반응을 육안으로 판정하였다. 실험은 총 33명(여 27명, 남 6명)의 성인남녀를 대상으로 하였으며, 판정 기준은 하기 표 1에 나타낸 국제접촉피부염연구회(ICDRG)의 기준에 따라 정하였다. Specifically, patches containing about 0.5 g each of purified water, Quillaja general extract or Quillaja radio frequency extract were attached to the back and removed after 24 hours, and skin reactions after 30 minutes, 24 hours, and 48 hours were visually determined. . The experiment was conducted on a total of 33 adult males and females (27 females, 6 males).
실험 결과는 하기 표 2에 나타내었다.The experimental results are shown in Table 2 below.
표 2에 나타낸 바와 같이 퀼라야 추출물은 일반 추출물뿐만 아니라 고주파 추출물 또한 모두 저자극으로 피부에 안전한 물질임을 확인하였다.As shown in Table 2, it was confirmed that the Quillaja extract is a safe material for the skin as both the general extract and the radiofrequency extract are hypoallergenic.
실험예 3: 퀼라야 고주파 추출물과 이를 포함하는 분무제의 소취 효과Experimental Example 3: Quillaja radio frequency extract and deodorizing effect of spray containing the same
가스검지관법을 통해 퀼라야 고주파 추출물의 소취 효과를 확인하고자 하였다.The purpose of this study was to confirm the deodorizing effect of Quillaja high frequency extract through the gas detection tube method.
구체적으로, 한국의류시험연구원(KATRI)에 의뢰하여 확인하였다. 의뢰기관에서 제공한 시험 조건은 다음과 같다Specifically, it was confirmed by requesting the Korea Apparel Testing and Research Institute (KATRI). The test conditions provided by the sponsoring organization are as follows.
1)시료 투입량: 50 ㎖1) Sample input amount: 50 ml
2)시험가스: 암모니아(NH3)2) Test gas: ammonia (NH 3 )
3)주입된 시험가스의 농도: 100 ㎍/㎖3) Concentration of injected test gas: 100 μg/ml
4)시험가스 주입량: 1.5 L4) Test gas injection volume: 1.5 L
5)시험 용기: 3 L 테틀러백5) Test vessel: 3 L tetler bag
6)시험환경: 온도 (20 ± 2) ℃, 습도 (40 ± 5) % RH6) Test environment: temperature (20 ± 2) ℃, humidity (40 ± 5) % RH
7)탈취력(%) = [(Blank가스농도-Sample가스농도)/Blank가스농도] x 1007) Deodorization power (%) = [(Blank gas concentration-Sample gas concentration)/Blank gas concentration] x 100
실험을 위한 분무제의 조성은 하기 표 3에 나타내었다. The composition of the spray agent for the experiment is shown in Table 3 below.
실험 결과는 하기 표 4에 나타내었다.The experimental results are shown in Table 4 below.
표 4에서와 같이 퀼라야 고주파 추출물과 이를 포함하는 조성물(제형예1)은 120분까지 99% 이상의 냄새를 제거하는 효과를 가졌다.As shown in Table 4, the Quillaja high frequency extract and the composition comprising the same (Formulation Example 1) had an effect of removing more than 99% of odors up to 120 minutes.
실험예 4: 퀼라야 고주파 추출물의 항바이러스 시험Experimental Example 4: Antiviral test of Quillaja high frequency extract
퀼라야 고주파 추출물의 항바이러스 활성을 알아보고자 ACE2에 결합하는 SARS-CoV-2 spike의 억제제 스크리닝을 실시 하였다.In order to investigate the antiviral activity of Quillaja high frequency extract, an inhibitor screening of SARS-CoV-2 spike binding to ACE2 was performed.
구체적으로, Coronavirus 2 (SARS-CoV-2)에 대한 항바이러스 실험은 Spike RBD(SARS-CoV-2): ACE2 Inhibitor Screening Assay Kit(Catalog # 79931)를 통해 확인하였다. 상기 Spike RBD(SARS-CoV-2) kit는 하기 표 5와 같은 구성으로 되어 있다.Specifically, the antiviral experiment for Coronavirus 2 (SARS-CoV-2) was confirmed through Spike RBD (SARS-CoV-2): ACE2 Inhibitor Screening Assay Kit (Catalog # 79931). The Spike RBD (SARS-CoV-2) kit is configured as shown in Table 5 below.
시험 방법은 키트 제조사에서 제공하는 매뉴얼(Assay Protocol)에 따라 진행하였으며, 모든 샘플들에 대해서는 2반복 실험하였다.Plate에 SARS-CoV-2 Spike를 코팅하기 위하여, 얼음 위에서 SARS-CoV-2 spike를 해동하였다. 해동된 시약 내용물은 적절히 분배하여 -80℃에 즉시 보관하였다. 이후에, PBS 용액으로 SARS-CoV-2 Spike를 1㎍/㎖농도로 희석하였다. Plate well에 상기 SARS-CoV-2 Spike 희석 용액을 50㎕씩 넣고, 4℃에서 하루동안 방치하였다. 그 후, 상기 well plate 용액을 버리고, 1x Immno buffer 1 용액 100㎕를 넣어 세척하였다. 이때 1x Immno buffer 1는 3x Immuno buffer 1을 멸균 증류수를 이용하여 희석한 것이다. 3차례 세척을 실시한 후, 깨끗한 종이 위에 plate를 탭하여 물기를 제거하였다. 이후에 plate well에 100㎕의 Blocking Buffer 2를 넣고, 실온에서 1시간 동안 느리게 흔들어 주었다. 이 후에, 상등액을 버리고, 상기 세척과정을 다시 실행하여 Plate에 SARS-CoV-2 Spike를 코팅하는 작업을 마무리 하였다.The test method was performed according to the manual (Assay Protocol) provided by the kit manufacturer, and all samples were tested twice. To coat the SARS-CoV-2 spike on the plate, the SARS-CoV-2 spike was applied on ice. thawed. Thawed reagent contents were dispensed appropriately and stored immediately at -80°C. Thereafter, SARS-CoV-2 Spike was diluted to a concentration of 1 μg/ml with PBS solution. 50 μl of the SARS-CoV-2 Spike dilution solution was added to the plate well and left at 4° C. for one day. After that, the well plate solution was discarded, and 100 μl of 1x Immno buffer 1 solution was added and washed. At this time, 1x Immno buffer 1 is diluted with 3x Immuno buffer 1 using sterile distilled water. After washing three times, tap the plate on clean paper to remove moisture. Thereafter, 100 μl of
SARS-CoV-2 Spike가 코팅된 각 well에 20㎕의 상기 1x Immuno Buffer를 넣고, 시험하고자하는 바이러스 저해 샘플 용액(Emodin)을 10㎕씩 넣었다. 동시에 양성 대조군(Emodin, Sigma Cat. #324694)과 Blank도 각각 10㎕씩 넣고, 모두 상온에서 1시간동안 방치하였다. 이후에, 각 well들은 하기 표 6의 조성대로 용액을 첨가하였다. 20 μl of the 1x Immuno Buffer was put into each well coated with SARS-CoV-2 Spike, and 10 μl of the virus inhibition sample solution (Emodin) to be tested was put into each well. At the same time, 10 μl of a positive control (Emodin, Sigma Cat. #324694) and a blank were also added, and both were left at room temperature for 1 hour. Thereafter, each well was added with a solution according to the composition of Table 6 below.
ACE2-His 용액은 얼음 위에서 해동한 뒤, 1x Immuno buffer 1로 2.5 ng/㎕가 되도록 희석하였다. 희석된 ACE2-His 용액 20㎕를 각 well들에 넣고, 1시간동안 상온에서 느리게 흔들어 반응시켰다. 그 후, 상등액을 버리고, 1x Immno buffer 1로 100㎕/well씩 3회 세척한 뒤, 깨끗한 종이 위에 plate를 탭하여 물기를 제거하였다. 이후, 각 well들에 Blacking Buffer 2를 100㎕씩 넣고 상온에 10분간 방치한 후, 상기 세척과정과 같은 방식대로 상등액을 버리고 well들을 세척하였다. 이후에, 상기 과정에서 희석된 ACE2-His 용액 20㎕을 Blocking Buffer 2로 Anti-His-HRP를 1000배 희석한 용액 100㎕으로 대체한 후 동일한 과정을 다시 수행하였다. 이후에 세척된 well들에 ELISA ECL Substrate A 50㎕와 ELISA ECL Substrate B 50㎕를 넣은 후, 즉시 reader기에 넣고 면역 반응시의 형광값을 측정하였다. 샘플내의 물질이 항바이러스 효과가 있을수록 형광값은 감소하며, 이를 Blank 대비 저해율을 계산하여 도2와 도3에 표기하였다.도 2는 실험의 양성대조군인 Emodin에 대한 결과를 나타낸 것이며, 도 3은 다른 농도의 퀼라야 고주파 추출물의 항바이러스 효과를 나타낸 것이다. After thawing on ice, the ACE2-His solution was diluted to 2.5 ng/μl with 1x Immuno buffer 1. 20 μl of the diluted ACE2-His solution was put into each well and reacted by shaking slowly at room temperature for 1 hour. Thereafter, the supernatant was discarded, washed 3 times with 100 μl/well of 1x Immno buffer 1, and tap the plate on clean paper to remove moisture. Then, 100 μl of
코로나바이러스의 Spike RBD(SARS-CoV-2): ACE2 Inhibitor로 알려진 Emodin을 양성대조군으로 하여 퀼라야 고주파 추출물과의 항바이러스 활성을 비교한 결과, SARS-CoV spike 단백질과 ACE-2의 결합 저해율이 Emodin은 56%인 반면, 10% 농도의 퀼라야 고주파 추출물은 99%의 저해율을, 100% 농도의 퀼라야 고주파 추출물은 100%의 저해율을 보였다. 이러한 사실을 통해 퀼라야 추출물은 기존의 항바이러스 물질인 Emodin보다 더욱 뛰어난 항바이러스 효능을 지님을 확인하였다.Spike RBD of coronavirus (SARS-CoV-2): As a result of comparing the antiviral activity with Quillaja high frequency extract using Emodin, known as the ACE2 Inhibitor, as a positive control, the binding inhibition rate of SARS-CoV spike protein and ACE-2 was While Emodin was 56%, the 10% concentration of Quillaja radiofrequency extract showed 99% inhibition, and the 100% concentration of Quillaja radiofrequency extract showed 100% inhibition. Through this fact, it was confirmed that the Quillaja extract has superior antiviral efficacy than Emodin, which is an existing antiviral substance.
삭제delete
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210023660A KR102347243B1 (en) | 2021-02-22 | 2021-02-22 | Composition for anti-virus comprising Quillaia saponaria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210023660A KR102347243B1 (en) | 2021-02-22 | 2021-02-22 | Composition for anti-virus comprising Quillaia saponaria |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102347243B1 true KR102347243B1 (en) | 2022-01-05 |
Family
ID=79348712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210023660A KR102347243B1 (en) | 2021-02-22 | 2021-02-22 | Composition for anti-virus comprising Quillaia saponaria |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102347243B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030045488A (en) * | 2001-12-04 | 2003-06-11 | 동방미래화학주식회사 | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC |
US20180325971A1 (en) * | 2016-07-29 | 2018-11-15 | Saponin Research Center S.A. | Use of quillaja saponaria extracts for the prevention and control of viral infections in fish |
-
2021
- 2021-02-22 KR KR1020210023660A patent/KR102347243B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030045488A (en) * | 2001-12-04 | 2003-06-11 | 동방미래화학주식회사 | The method of manufacturing of the extract from the Platycodon grandiflorum A. DC |
US20180325971A1 (en) * | 2016-07-29 | 2018-11-15 | Saponin Research Center S.A. | Use of quillaja saponaria extracts for the prevention and control of viral infections in fish |
Non-Patent Citations (4)
Title |
---|
Journal of General Virology, 2007, 88(1), 275-285* * |
Michael R. Roner et al., Future Med Chem. (2010), 2(7),1083-1097 |
Michael R. Roner et al., Journal of General Virology (2007), 88, 275-285 |
Waller, G.R. & Yamasaki, K. (1996) Saponins used in traditional and modern medicine, Plenum Press, New York, NY. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4205188B2 (en) | Maillard reaction inhibitor | |
US20060233738A1 (en) | Composition for promoting production of type 1 collagen and/or elastin | |
JP2002241299A (en) | Maillard reaction recovering agent | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR101800498B1 (en) | Composition for improving skin wrinkle comprising extract or compounds derived from unripe apple | |
KR100633380B1 (en) | Compositions of oriental cosmetics for atopy skin containing mixture of specific herbal extracts | |
JP6981664B2 (en) | Nourishing tonic | |
JP6895860B2 (en) | Slimming foods and topical compositions | |
KR20170121532A (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR102347243B1 (en) | Composition for anti-virus comprising Quillaia saponaria | |
KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR102598905B1 (en) | Deodorant composition comprising Quillaia saponaria | |
KR101610894B1 (en) | Taste-masked granules containing vitamin C | |
JP4169814B2 (en) | A topical skin preparation containing agave or sisal extract | |
JPH11139985A (en) | Physiologically active composition derived from hydrolyzate of keratinous protein | |
KR101069906B1 (en) | A composition for improving skin conditions comprising extract of Aster subulatus Michx. | |
JP2003176230A (en) | Collagen production promoter, elastase inhibitor, collagenase inhibitor and skin cosmetic and beautifying foods or beverage | |
JP2004002361A (en) | Anti-influenza virus agent | |
KR20230124384A (en) | Composition for anti-virus comprising extract from curled dock | |
KR20230124508A (en) | Composition for anti-virus comprising extract from reynoutria japonica | |
KR102578871B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
KR102540384B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component | |
KR102676865B1 (en) | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |